Effektivität und Therapietreue der Velumount-Anwendung bei sozial untragbarem Schnarchen und leichtem bis mittelschwerem Schlafapnoe-Syndrom; Resultate einer Pilotstudie

Effectiviteit en therapietrouw van de Velumount-methode bij sociaal onaanvaardbaar snurken en lichte
tot matig ernstige OSAS; resultaten van een pilotstudie

A.J.G. de Bruijn, R. van Blommestein
Nederlands Tijdschrift voor Keel-Neus-Oorheelkunde | 2010 | 16 e  jaargang | nr. 2

Purpose: this prospective pilot-study was performed to investigate the effectiveness of the Velumount- method  as  a  relatively  new  treatment  for  socially unacceptable snoring (SUS) as well as for mild to moderate obstructive sleep apnea syndrome (OSAS). Also the occurrence of side effects was evaluated. Patients  and  methods:  29  patients  (22  men  and  7 women)  were  included  after  providing  informed consent. All patients could be considered as heavy snorers with a snoring index ≥7. In this group of patients there were 15  subjects without OSAS (AHI moderate  OSAS  (15/h≥AHIment  of  the  Velumount,  level  III  ambulant  polygraphy  (PG)  was  done  to  obtain  respiratory  parameters.  After  adjustment  of  the  Velumount,  PG was performed only in the tolerance group containing those patients who were able, after a period of habituation, to wear the device comfortably during the  most  of  the  night.  The  Calgary  Sleep  Apnea Quality of Life Index (SAQLI) was used to evaluate changes in quality of life.

Results:  the  tolerance  group  contains  22  patients. For this group the snoring index improved from an average of 8.2 (±0,8) to 2.7 (±1,9) (pthe average apnea index, hypopnea index and apnea-hyponea index improved signifi cantly (psuccessful treatment is defined as an apnea-hypopnea index respect  to  the  index  before  treatment,  seven  out of nine patients of the tolerance group fulfi l these criteria.  With  the  SAQLI  no  clinically  signifi cant improvement was found in the quality of life in the tolerance  group.  The  most  frequently  mentioned side effect was hypersalivation; it was found in four patients in the tolerance group. Eventually, after a mean follow-up period of 73 days (range 62-91) 20 patients  indicated  that  they  intended  to  continue using the Velumount. This results in a compliance ratio of 69%.

Conclusion: the Velumount-method is an effective treatment against SUS with an acceptable compli- ance. The Velumount also seems to be a promising treatment  for  mild  to  moderate  OSAS.  Especially in patients who are not suitable for treatment with a  mandibular  repositioning  appliance  or  palatal surgery,  the  Velumount  device  could  be  a  good alternative.

Schlussfolgerung: Die Velumount-Methode ist eine effektive Therapie gegen Schnarchen mit akzeptabler Therapietreue. Velumount scheint auch eine vielversprechende Therapie bei mildem bis mittlerem Schlafapnoe-Syndrom zu sein.